146 related articles for article (PubMed ID: 35155300)
1. Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer.
Byun YJ; Kang HW; Piao XM; Zheng CM; Moon SK; Choi YH; Kim WT; Lee SC; Yun SJ; Kim WJ
Prostate Int; 2022 Mar; 10(1):1-6. PubMed ID: 35155300
[TBL] [Abstract][Full Text] [Related]
2. Urinary MicroRNAs of Prostate Cancer: Virus-Encoded hsv1-miRH18 and hsv2-miR-H9-5p Could Be Valuable Diagnostic Markers.
Yun SJ; Jeong P; Kang HW; Kim YH; Kim EA; Yan C; Choi YK; Kim D; Kim JM; Kim SK; Kim SY; Kim ST; Kim WT; Lee OJ; Koh GY; Moon SK; Kim IY; Kim J; Choi YH; Kim WJ
Int Neurourol J; 2015 Jun; 19(2):74-84. PubMed ID: 26126436
[TBL] [Abstract][Full Text] [Related]
3. Increased Expression of Herpes Virus-Encoded hsv1-miR-H18 and hsv2-miR-H9-5p in Cancer-Containing Prostate Tissue Compared to That in Benign Prostate Hyperplasia Tissue.
Yun SJ; Jeong P; Kang HW; Shinn HK; Kim YH; Yan C; Choi YK; Kim D; Ryu DH; Ha YS; Kim TH; Kwon TG; Kim JM; Suh SH; Kim SK; Kim SY; Kim ST; Kim WT; Lee OJ; Moon SK; Kim NH; Kim IY; Kim J; Cha HJ; Choi YH; Cha EJ; Kim WJ
Int Neurourol J; 2016 Jun; 20(2):122-30. PubMed ID: 27377944
[TBL] [Abstract][Full Text] [Related]
4. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone.
Kang HW; Byun YJ; Moon SM; Kim K; Piao XM; Zheng CM; Moon SK; Choi YH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2022 Mar; 63(2):238-244. PubMed ID: 35244999
[TBL] [Abstract][Full Text] [Related]
5. Erratum: Increased Expression of Herpes Virus-Encoded hsv1-miR-H18 and hsv2-miR-H9-5p in Cancer-Containing Prostate Tissue Compared to That in Benign Prostate Hyperplasia Tissue.
Yun SJ; Jeong P; Kang HW; Shinn HK; Kim YH; Yan C; Choi YK; Kim D; Ryu DH; Ha YS; Kim TH; Kwon TG; Kim JM; Suh SH; Kim SK; Kim SY; Kim ST; Kim WT; Lee OJ; Moon SK; Kim NH; Kim IY; Kim J; Cha HJ; Choi YH; Cha EJ; Kim WJ
Int Neurourol J; 2016 Dec; 20(4):374. PubMed ID: 28043100
[TBL] [Abstract][Full Text] [Related]
6. Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer.
Byun YJ; Piao XM; Jeong P; Kang HW; Seo SP; Moon SK; Lee JY; Choi YH; Lee HY; Kim WT; Lee SC; Cha EJ; Yun SJ; Kim WJ
Investig Clin Urol; 2021 May; 62(3):340-348. PubMed ID: 33834642
[TBL] [Abstract][Full Text] [Related]
7. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
8. Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role.
Cochetti G; Poli G; Guelfi G; Boni A; Egidi MG; Mearini E
Onco Targets Ther; 2016; 9():7545-7553. PubMed ID: 28008272
[TBL] [Abstract][Full Text] [Related]
9. Detection of miRNAs in urine of prostate cancer patients.
Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
[TBL] [Abstract][Full Text] [Related]
10. Semen miRNAs Contained in Exosomes as Non-Invasive Biomarkers for Prostate Cancer Diagnosis.
Barceló M; Castells M; Bassas L; Vigués F; Larriba S
Sci Rep; 2019 Sep; 9(1):13772. PubMed ID: 31551516
[TBL] [Abstract][Full Text] [Related]
11. Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification.
Al-Kafaji G; Said HM; Alam MA; Al Naieb ZT
Oncol Lett; 2018 Jul; 16(1):1357-1365. PubMed ID: 30061955
[TBL] [Abstract][Full Text] [Related]
12. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
[TBL] [Abstract][Full Text] [Related]
13. A herpes simplex virus type 2-encoded microRNA promotes tumor cell metastasis by targeting suppressor of cytokine signaling 2 in lung cancer.
Wang X; Liu S; Zhou Z; Yan H; Xiao J
Tumour Biol; 2017 May; 39(5):1010428317701633. PubMed ID: 28468588
[TBL] [Abstract][Full Text] [Related]
14. MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia.
Abramovic I; Vrhovec B; Skara L; Vrtaric A; Nikolac Gabaj N; Kulis T; Stimac G; Ljiljak D; Ruzic B; Kastelan Z; Kruslin B; Bulic-Jakus F; Ulamec M; Katusic-Bojanac A; Sincic N
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922968
[TBL] [Abstract][Full Text] [Related]
15. Combinations of elevated tissue miRNA-17-92 cluster expression and serum prostate-specific antigen as potential diagnostic biomarkers for prostate cancer.
Feng S; Qian X; Li H; Zhang X
Oncol Lett; 2017 Dec; 14(6):6943-6949. PubMed ID: 29163712
[TBL] [Abstract][Full Text] [Related]
16. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
[TBL] [Abstract][Full Text] [Related]
17. Challenges in Cancer Biomarker Discovery Exemplified by the Identification of Diagnostic MicroRNAs in Prostate Tissues.
Ambrozkiewicz F; Karczmarski J; Kulecka M; Paziewska A; Cybulska M; Szymanski M; Dobruch J; Antoniewicz A; Mikula M; Ostrowski J
Biomed Res Int; 2020; 2020():9086829. PubMed ID: 32462034
[TBL] [Abstract][Full Text] [Related]
18. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
19. The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease.
Kurul NO; Ates F; Yilmaz I; Narli G; Yesildal C; Senkul T
Prostate; 2019 Jul; 79(10):1125-1132. PubMed ID: 31045265
[TBL] [Abstract][Full Text] [Related]
20. miR-301a expression: A prognostic marker for prostate cancer.
Damodaran C; Das TP; Papu John AM; Suman S; Kolluru V; Morris TJ; Faber EN; Rai SN; Messer JC; Alatassi H; Ankem MK
Urol Oncol; 2016 Aug; 34(8):336.e13-20. PubMed ID: 27133223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
